| Document |
Document Title |
|
WO/2009/144278 |
An enriched conglutin-γ protein extract from lupin seeds having a % by weight of conglutin-γ between 10 and 30%, or a conglutin-γ protein, or functional derivatives thereof for use as a medicament, as food integrator or diet supplemen...
|
|
WO/2009/145238 |
Disclosed is a CD8-positive regulatory T cell which is more practical for an immune-related disease in an animal including a human body. A CD8-positive CXCR3-positive T cell is used as an immunomodulatory agent.
|
|
WO/2009/145590 |
The present invention relates to a novel piperazine derivative or pharmaceutically acceptable salt thereof, a process for preparing the same, a pharmaceutical composition for treating central nervous system diseases comprising an effecti...
|
|
WO/2009/146033 |
The present invention provides novel genetic modifiers of SMN function. In particular, the present invention provides methods of treating spinal muscular atrophy (SMA) in a subject in need thereof by manipulating specific genes in the BM...
|
|
WO/2009/144093 |
Hydroxytyrosol or olive juice containing hydroxytyrosol can be used to maintain or increase mitochondrial biogenesis in cardiac muscle, skeletal muscles, and liver tissue.
|
|
WO/2009/145590 |
The present invention relates to a novel piperazine derivative or pharmaceutically acceptable salt thereof, a process for preparing the same, a pharmaceutical composition for treating central nervous system diseases comprising an effecti...
|
|
WO/2009/146033 |
The present invention provides novel genetic modifiers of SMN function. In particular, the present invention provides methods of treating spinal muscular atrophy (SMA) in a subject in need thereof by manipulating specific genes in the BM...
|
|
WO/2009/144278 |
An enriched conglutin-γ protein extract from lupin seeds having a % by weight of conglutin-γ between 10 and 30%, or a conglutin-γ protein, or functional derivatives thereof for use as a medicament, as food integrator or diet supplemen...
|
|
WO/2009/146310 |
This disclosure relates to deuterated Tizanidine, to compositions comprising the compound of this disclosure and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by- administering ...
|
|
WO/2009/144093 |
Hydroxytyrosol or olive juice containing hydroxytyrosol can be used to maintain or increase mitochondrial biogenesis in cardiac muscle, skeletal muscles, and liver tissue.
|
|
WO/2009/144481 |
A construct comprising a cell delivery peptide covalently attached to a biologically active compound suitable for delivery of said biologically active compound into cells, wherein optionally the cells are cardiac muscle, skeletal muscle,...
|
|
WO/2009/141159 |
Compounds of formula (I): wherein R1, R2, R3, and n are as defined herein, are useful for the treatment or prophylaxis of Duchenne muscular dystrophy, Becker muscular dystrophy, or cachexia.
|
|
WO/2009/142195 |
Disclosed is a method for inducing/maintaining remission of an immune disease, which can reduce serious adverse side effects and stress in a patient. After the induction of remission of an immune disease with a biological substance or a ...
|
|
WO/2009/142321 |
The present invention is related to study on synthesis of a novel thiophenediamine derivative having a urea structure and finding of a pharmacological action of the derivative. Specifically, the present invention provides a compound rep...
|
|
WO/2009/139876 |
Muscle tissue regeneration is one of the most important homeostatic processes of adult skeletal muscle, which after development retains the capacity to regenerate in response to different type of stimuli, including a direct trauma or neu...
|
|
WO/2009/140448 |
The present invention provides a compound of the Formula (I), or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising a compound of Formula (I) in combination with a suitable carrier, diluent, or excipient; ...
|
|
WO/2009/139361 |
Disclosed is a glucocorticoid receptor agonist composed of a compound represented by formula (1) or a salt thereof, which is a 2,2,4-trimethyl-6-phenyl-1,2-dihydroquinoline derivative having a substituted oxy group. A novel pharmacologi...
|
|
WO/2009/137880 |
The invention provides a method of treating a disorder characterised by elevated or dysregulated myostatin, disorders where the interaction between follistatin and angiogenin can be used to improve function in tissues, neurological disea...
|
|
WO/2009/137879 |
The invention provides a method of treatment of any disorder in which administration of angiogenin is beneficial wherein the angiogenin is administered orally. Particularly, the oral angiogenin does not require a carrier or excipient or ...
|
|
WO/2009/140448 |
The present invention provides a compound of the Formula (I), or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising a compound of Formula (I) in combination with a suitable carrier, diluent, or excipient; ...
|
|
WO/2009/133905 |
Disclosed is a pharmaceutical composition for the treatment or prevention of a disease which can be prevented or treated through the inhibition of the activity of human FGF-23 protein. Specifically disclosed is a peptide comprising an am...
|
|
WO/2009/133861 |
Disclosed is a cyclic amine compound useful as an androgen receptor modulator. [In formula (I), R1 represents a hydrogen atom, a halogen atom or the like; R2 represents a hydrogen atom, a halogen atom or the like; R3 represents a heteroc...
|
|
WO/2009/131201 |
Disclosed are: a therapeutic agent for intermittent claudication, which comprises a tricyclic compound represented by formula (I) [wherein R1 represents a substituted or unsubstituted lower alkyl] or a pharmacologically acceptable salt t...
|
|
WO/2009/129501 |
Disclosed herein are compounds, compositions, and methods for enhancing smooth muscle function in a subject by administration of soluble epoxide hydrolase inhibitors and for treating subjects with smooth muscle disorders including erecti...
|
|
WO/2009/128481 |
Disclosed is a glucokinase activator which is useful as a pharmaceutical agent such as a prophylactic/therapeutic agent for diabetes, obesity and others. Specifically disclosed is a compound represented by formula (I) [wherein each symbo...
|
|
WO/2009/128558 |
Disclosed is a compound represented by general formula (I) or a pharmacologically acceptable salt thereof, which can be used as an activator for a PPAR. (In the formula, R1 and R2 independently represent a hydrogen atom, an alkyl group h...
|
|
WO/2009/124693 |
The present invention relates to 2,3-dimethoxy-5-methyl-6-(10-hydroxydecyl)-1,4- benzoquinone (idebenone) for treating and/or preventing respiratory illness associated with certain forms of muscular dystrophy.
|
|
WO/2009/126350 |
Anti-K63-linked polyubiquitin monoclonal antibodies, and methods for using the antibodies, are provided.
|
|
WO/2009/123316 |
Disclosed is an sGC activator, particularly a compound which is useful for the prevention or treatment of diseases including hypertension, ischemic heart diseases, heart failure, kidney diseases, arteriosclerotic diseases, atrial fibrill...
|
|
WO/2009/121623 |
Compounds of formula (I): wherein X, L1, R1, L2, R2, R3, and R4 are as defined herein, are useful in the treatment or prophylaxis of Duchenne muscular dystrophy, Becker muscular dystrophy, or cachexia.
|
|
WO/2009/123174 |
A medicinal preparation for patients having a neutralizing antibody against a botulinum toxin originating in a Clostridium botulinum type A1 strain (type A1 botulinum toxin) characterized by comprising as the active ingredient a 150 kDa ...
|
|
WO/2009/121623 |
Compounds of formula (I): wherein X, L1, R1, L2, R2, R3, and R4 are as defined herein, are useful in the treatment or prophylaxis of Duchenne muscular dystrophy, Becker muscular dystrophy, or cachexia.
|
|
WO/2009/123221 |
Disclosed is a prophylactic or therapeutic agent for nerve diseases such as ischemic brain diseases and neurodegenerative diseases or the like or a prophylactic or therapeutic agent for diseases for which an antioxidant activity is effec...
|
|
WO/2009/120815 |
|
|
WO/2009/120304 |
Agonists of a non-proteolytically activated thrombin receptor, and more particularly, thrombin peptide derivatives, can be used in methods to cause smooth muscle relaxation. Compositions comprising thrombin peptide derivatives can be adm...
|
|
WO/2009/120815 |
|
|
WO/2009/115321 |
The present invention relates to substituted imidazopyrimidine derivatives, substituted imidazopyrazine derivatives and substituted imidazopyridazine derivatives as melanocortin-4 receptor (MC-4R) modulators, in particular as melanocorti...
|
|
WO/2009/115321 |
The present invention relates to substituted imidazopyrimidine derivatives, substituted imidazopyrazine derivatives and substituted imidazopyridazine derivatives as melanocortin-4 receptor (MC-4R) modulators, in particular as melanocorti...
|
|
WO/2009/114597 |
Compositions containing apoaequorin and methods for their use in treating symptoms and disorders related to calcium imbalances associated with, for example, sleep quality, energy quality, mood quality, memory quality or pain are provided...
|
|
WO/2009/105691 |
Methods are provided herein for treatment of myotonic dystrophy and other toxic RNA diseases in a subject. In some examples, the method comprises administration of a compound that binds a nucleotide repeat expansion in a ribonucleic acid...
|
|
WO/2009/104388 |
Disclosed is a prophylactic/therapeutic agent for collagenosis, which can inhibit the function of TREM-1 to exhibit a prophylactic/therapeutic effect on collagenosis. Also disclosed is a method for the screening of a prophylactic/therape...
|
|
WO/2009/104807 |
In one embodiment, provided is a composition comprising a prostaglandin compound for modulating stem cell proliferation and/or differentiation in a mammalian subject. In another embodiment, the instant application is a composition compri...
|
|
WO/2009/105691 |
Methods are provided herein for treatment of myotonic dystrophy and other toxic RNA diseases in a subject. In some examples, the method comprises administration of a compound that binds a nucleotide repeat expansion in a ribonucleic acid...
|
|
WO/2009/101399 |
A method of correcting expression of a gene in a human cell having a muscle disease or muscular dystrophy phenotype, wherein without correction the gene fails to express functional protein due to one or more mutations, said method compri...
|
|
WO/2009/101137 |
We disclose the use of 25-OH D3 (calcifediol) to increase muscle strength, muscle function, or both. Vitamin D3 (cholecalciferol) may optionally be used together with 25-OH D3. Forms and dosages of a pharmaceutical composition, as well a...
|
|
WO/2009/099326 |
The current invention provides for methods and medicaments that apply an oligonucleotide comprising aninosine and/or an uracile and/or a nucleotide containing a base able to form a wobble base pair, said oligonucleotide being preferably ...
|
|
WO/2009/098533 |
The present invention relates to the use of a non-immunosuppressive cyclosporin A derivative for preventing or reducing muscular degeneration in a subject suffering from Limb-Girdle muscular Dystrophy.
|
|
WO/2009/098577 |
The present invention relates to the use of a non-immunosuppressive cyclosporin A derivative for preventing or reducing muscular degeneration in a subject suffering from Limb-Girdle muscular Dystrophy.
|
|
WO/2009/098577 |
The present invention relates to the use of a non-immunosuppressive cyclosporin A derivative for preventing or reducing muscular degeneration in a subject suffering from Limb-Girdle muscular Dystrophy.
|
|
WO/2009/095378 |
The invention provides methods for the diagnosis and treatment of musculoskeletal disorders relating to the Hedgehog pathway, including but not limited to muscular dystrophy (e.g., Duchenne Muscular Dystrophy) using agents that agonize S...
|
